Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lyfgenia
Pharma
bluebird investors get on board with sale to Carlyle, SK Capital
Carlyle and SK Capital expect to complete the acquisition of bluebird bio on Monday.
Kevin Dunleavy
May 30, 2025 11:50am
Once valued at $10B, struggling bluebird bio sold for $29M
Feb 21, 2025 10:56am
Bluebird bio lays off 25% of workforce
Sep 24, 2024 10:19am
Bluebird down 18% with slow uptake of SCD gene therapy Lyfgenia
Aug 14, 2024 12:07pm
HHS provides unfavorable opinion on bluebird's fertility program
Jul 22, 2024 5:26pm
With 64 centers activated, bluebird is ready to grow Lyfgenia
May 9, 2024 1:40pm
